Fintel reports that on July 1, 2025, Cantor Fitzgerald initiated coverage of Trevi Therapeutics (NasdaqGM:TRVI) with a ...

Trevi Therapeutics plans to begin a Phase 3 trial for IPF chronic cough in the first half of 2026, with projected enrollment completion within a year and topline data expected by mid-2027.

Trevi plans to initiate its Phase 3 program in the first half of 2026 after an End-of-Phase 2 meeting with the FDA. Additionally, Trevi Therapeutics launched a $100 million public offering of common ...

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients ...

Find the latest analyst research, reports, and ratings for Trevi Therapeutics, Inc. Common Stock (TRVI) at Nasdaq.com.

Advanced lab-grown tissues help show how special lung cells develop, shedding light on rare ACDMPV disease and suggesting potential ways to repair damage from viral infections such as COVID-19 ...